michael atkins, md, regarding the keynote 426 phase iii trial in metastatic renal cell carcinoma
Published 5 years ago • 112 plays • Length 0:58
Download video MP4
Download video MP3
Similar videos
-
0:44
rana mckay, md, elaborates on the outcomes of the keynote 426 phase iii study in mrcc
-
0:44
michael atkins, md, on follow up investigation of checkmate 025 in renal cell carcinoma patients
-
1:20
michael atkins, md, offers opinion on io-tki combinations in renal cell cancer
-
2:16
updated results from keynote-426 for metastatic kidney cancer
-
0:51
michael atkins, md, shares exciting potential of current late-stage clinical studies in rcc patients
-
1:04
tian zhang, md, elaborates on the outcomes of keynote 426 presented at gu 2019
-
8:32
dr. michael b. atkins on treating advanced kidney cancer
-
0:40
michael atkins, md, considers how to treat mrcc after combination i-o in the 1st line setting
-
0:55
michael atkins, md, on mrcc patients whose cancer returns and were previously treated with i-o
-
0:26
michael atkins, md, regarding single agent tkis in the 1st line setting
-
0:41
michael atkins, md, on appropriate patient types to receive a tki in the treatment of 1st line rcc
-
1:37
michael b. atkins, md, comments on clinical trials investigating the use of i-o and tkis in rcc
-
2:01
michael atkins, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients
-
1:08
michael b. atkins, md, on the role of imdc classification in treatment decision-making
-
1:15
michael b. atkins, md, on selecting i-o and tki combinations for the treatment of 1st line rcc
-
0:52
michael b. atkins, md, considers preferred agents in the treatment of rcc in the 2nd line
-
0:38
michael atkins, md, considers intermediate/poor & favorable risk rcc patients
-
2:13
tian zhang, md, shares thoughts on the pdigree trial in metastatic, untreated rcc
-
1:21
rana mckay, md, considers the implications of checkmate 214 & keynote-426 presented at gu 2019
Clip.africa.com - Privacy-policy